132 related articles for article (PubMed ID: 16010049)
1. Oligodendrogliomas: impact of molecular genetics on treatment.
Hartmann C; von Deimling A
Neurol India; 2005 Jun; 53(2):140-8. PubMed ID: 16010049
[TBL] [Abstract][Full Text] [Related]
2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
3. Pathology and molecular genetics of oligodendroglial tumors.
Hartmann C; Mueller W; von Deimling A
J Mol Med (Berl); 2004 Oct; 82(10):638-55. PubMed ID: 15322700
[TBL] [Abstract][Full Text] [Related]
4. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.
Bauman GS; Ino Y; Ueki K; Zlatescu MC; Fisher BJ; Macdonald DR; Stitt L; Louis DN; Cairncross JG
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):825-30. PubMed ID: 11020580
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of oligodendroglioma.
van den Bent MJ
Semin Oncol; 2004 Oct; 31(5):645-52. PubMed ID: 15497117
[TBL] [Abstract][Full Text] [Related]
6. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic evidence for subtypes of oligoastrocytomas.
Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic analysis of oligodendroglial tumors.
Hartmann C; Mueller W; Lass U; Kamel-Reid S; von Deimling A
J Neuropathol Exp Neurol; 2005 Jan; 64(1):10-4. PubMed ID: 15715080
[TBL] [Abstract][Full Text] [Related]
9. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of chromosome 1p and 19q status and expression of R132H mutant IDH1 protein in oligodendroglial tumors].
Yao K; Duan Z; Hu Z; Bian Y; Qi X
Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):663-7. PubMed ID: 25567591
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology of oligodendroglial tumors.
Hartmann C; von Deimling A
Recent Results Cancer Res; 2009; 171():25-49. PubMed ID: 19322536
[TBL] [Abstract][Full Text] [Related]
12. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
13. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma.
Kraus JA; Koopmann J; Kaskel P; Maintz D; Brandner S; Schramm J; Louis DN; Wiestler OD; von Deimling A
J Neuropathol Exp Neurol; 1995 Jan; 54(1):91-5. PubMed ID: 7815084
[TBL] [Abstract][Full Text] [Related]
14. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
15. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.
Reifenberger G; Louis DN
J Neuropathol Exp Neurol; 2003 Feb; 62(2):111-26. PubMed ID: 12578221
[TBL] [Abstract][Full Text] [Related]
16. Oligodendroglioma: pathology, molecular mechanisms and markers.
Wesseling P; van den Bent M; Perry A
Acta Neuropathol; 2015 Jun; 129(6):809-27. PubMed ID: 25943885
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
18. New treatment paradigm for patients with anaplastic oligodendroglial tumors.
Polivka J; Polivka J; Rohan V; Topolcan O
Anticancer Res; 2014 Apr; 34(4):1587-94. PubMed ID: 24692686
[TBL] [Abstract][Full Text] [Related]
19. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
Sonabend AM; Lesniak MS
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
